Insider · CIK 0001839046
Cheryl Gault
Files at RAPP (Rapport Therapeutics, Inc.). First filing Sep 10, 2025, latest Oct 1, 2026.
Cheryl Gault files SEC Form 4 as COO at RAPP (Rapport Therapeutics, Inc.). Since Sep 10, 2025, Cheryl Gault has reported 0 open-market buys worth $0 and 5 open-market sells worth $1.0M, the latest filed on Oct 1, 2026.
A track record needs three past buys with six months of prices behind them; Cheryl Gault has 0, so none is measured yet.
The newest scored trade: sold $332k of RAPP on Sep 30, 2026, filed Oct 1, 2026, scored 23 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $822k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RAPP: Rapport Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Rapport Therapeutics, Inc. | $332k 10,000 shares | -7% | +38% from low-36% from high | |
| 22Weak | Rapport Therapeutics, Inc. | $282k 10,000 shares | -6% | +235% from low-13% from high | |
| 27Weak | RAPPsell Rapport Therapeutics, Inc. | $58k 2,014 shares | -1% | +267% from low-7% from high | |
| 11Weak | Rapport Therapeutics, Inc. | $150k 5,000 shares | -3% | +312% from low-6% from high | |
| 12Weak | Rapport Therapeutics, Inc. | $192k 5,000 shares | -3% | +340% from low0% from high |
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,925 | $33.04 | $262k | 141,989 | 12 d ago |
| Sep 30, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,075 | $33.76 | $70k | 139,914 | 12 d ago |
| Mar 30, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,161 | $28.04 | $201k | 162,753 | Mar 31, 2026 |
| Mar 30, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,839 | $28.55 | $81k | 159,914 | Mar 31, 2026 |
| Mar 5, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock | -2,014 | $28.93 | $58k | 169,914 | Mar 9, 2026 |
| Feb 2, 2026 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +132,000 | $0.00 | $0 | 132,000 | Feb 4, 2026 |
| Nov 26, 2025 | RAPP Rapport Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +5,000 | $1.80 | $9,000 | 176,928 | Dec 1, 2025 |
| Nov 26, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $30.10 | $150k | 171,928 | Dec 1, 2025 |
| Nov 26, 2025 | RAPP Rapport Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 105,407 | Dec 1, 2025 |
| Sep 8, 2025 | RAPP Rapport Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +5,000 | $1.80 | $9,000 | 176,928 | Sep 10, 2025 |
| Sep 8, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $38.33 | $192k | 171,928 | Sep 10, 2025 |
| Sep 8, 2025 | RAPP Rapport Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 110,407 | Sep 10, 2025 |
| Mar 3, 2025 | RAPP Rapport Therapeutics, Inc. | AGrant or award Common Stock | +13,987 | $0.00 | $0 | 171,928 | Mar 5, 2025 |
| Feb 3, 2025 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +129,000 | $0.00 | $0 | 129,000 | Feb 4, 2025 |
Questions about Cheryl Gault
Answered from the filings on this page, as of the latest one.
Is Cheryl Gault buying or selling?
In the last 12 months Cheryl Gault reported 0 open-market buys worth $0 and 4 open-market sells worth $822k on SEC Form 4; the latest was sold $332k of RAPP on Sep 30, 2026. Grants, option exercises and tax withholding are not counted.
How did Cheryl Gault's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Cheryl Gault has 0.
Where does Cheryl Gault file Form 4?
Cheryl Gault has filed Form 4 at RAPP (Rapport Therapeutics, Inc.) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.